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Abstract
Chronic kidney disease (CKD) is a world-wide public health problem, with adverse outcomes of kidney failure, cardiovascular 
disease, and premature death. This finding has led to the hypothesis that earlier recognition of kidney disease and successful 
intervention may improve outcome. The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative 
(K/DOQI), and other National institutions recommend glomerular filtration rate (GFR) for the definition, classification, screening, 
and monitoring of CKD. Blood creatinine clearance, the most widely used clinical marker of kidney function, is now recognized 
as an unreliable measure of GFR because serum creatinine is affected by age, weight, muscle mass, race, various medica-
tions, and extra-glomerular elimination. Cystatin C concentration is a new and promising marker for kidney dysfunction in both 
native and transplanted kidneys. Because of its low molecular weight, cystatin C is freely filtered at the glomerulus and is almost 
completely reabsorbed and catabolized, but not secreted, by tubular cells. Given these characteristics, cystatin C concentra-
tion may be superior to creatinine concentration in detecting chronic kidney disease. This review aims to evaluate from recent 
literature the clinical efficiency and relevance of these GFR markers in terms of screening CKD.
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Measures of renal function are important and commonly 
used in most clinical investigations. Their routine use is grow-
ing rapidly with the increasing incidence of chronic kidney 
disease (CKD) worldwide as a consequence population ag-
ing and the increasing incidence of type 2 diabetes mellitus 
(1). Consequently, patients with diabetes and hypertension 
are particularly affected by CKD. Most patients with CKD are 
identified or treated after a considerable delay. Early identi-
fication is critical to delay progression of CKD to end-stage 
renal disease and to reduce the cardiovascular co-morbidity 
associated with CKD. At the first meeting for the global defi-
nition and classification of CKD in 2004, the independent 
international Kidney Disease Improving Global Outcome 
organization (KDIGO) recommended two laboratory tests 
for an earlier detection of CKD. The tests are: estimation of 
glomerular filtration rate (GFR), which is the best estimate of 
renal function, using the simplified equation derived from the 
Modification of Diet in Renal Disease Study (MDRD), and 
determination of proteinuria, preferably microalbuminuria, 
corrected for urinary creatinine. On this basis, kidney dam-
age is defined as structural or functional abnormalities of the 
kidney, with or without decreased GFR. Markers of kidney 
damage include proteinuria, abnormalities of urine sediment, 
abnormalities in imaging tests, or abnormalities of blood or 
urine composition specific for certain syndromes. CKD is also 
defined if the GFR is <60 mL·min-1·1.73 (m2)-1 for ≥3 months, 
with or without kidney damage. These recommendations have 
been accepted by the nephrological community (2,3).
Measurement of glomerular filtration rate
GFR cannot be measured directly in humans. Rather, 
it has to be determined by measuring the clearance of an 
ideal filtration marker, which has to be freely filtered at the 
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level of the glomerulus. Thus, the molecular weight of such 
a marker has to be low and the compound must not bind to 
plasma proteins. The ideal marker must be able to achieve 
a stable plasma concentration, is not reabsorbed, secreted 
or metabolized by the kidney, is physiologically inert and 
does not alter renal function. Inulin, an uncharged polymer 
of fructose derived from plant tubers, fulfills these require-
ments. Thus, inulin may be regarded as the gold standard 
against which other filtration markers for estimating GFR 
must be compared. However, the use of inulin requires 
continuous intravenous infusion and multiple, timed urine 
collections. Furthermore, inulin measurement is expensive, 
cumbersome and not routinely available. Consequently, 
inulin is only used in research studies when very accurate 
estimation of renal function is necessary (4,5). 
Several compounds labeled with radioisotopes have 
been used for the assessment of GFR. Among these are 
125I-iothalamate, 99mTc-diethylenethiaminepenta-acetic 
acid (99mTc-DTPA) and 51Cr-ethylenediaminetetra-acetic 
acid (51Cr-EDTA). All these compounds have a low molecu-
lar weight and their plasma protein binding and extrarenal 
elimination are negligible. Thus, they fulfill some of the es-
sential criteria for a renal filtration marker. The advantage 
of these substances is their ease of administration as well 
as the simplicity, accuracy and precision of their measure-
ment. These properties enable the plasma concentra-
tion vs time curve after intravenous bolus injection to be 
measured easily. From the plasma concentration vs time 
curves obtained, the total body clearance can be calculated 
using pharmacokinetic models, usually a two-compartment 
model. Intrinsic to the use of radioactive substances is 
concern about radiation exposure, particularly in women 
of child-bearing age. For the substances mentioned above, 
the whole body radiation exposure achieved as a result of 
a single clearance measurement with the usual doses is 
lower than that received from a chest X-ray (4,5). Another 
important consideration is that the terminal elimination 
phase is significantly prolonged in advanced renal failure. In 
patients with moderate renal failure (GFR between 30 and 
59 mL/min) samples are taken for up to 5 h after injection, 
whereas in patients with advanced renal failure samples 
are required for up to 24 h after injection (6).
Although they are adequate methods, they are less 
accurate than two- and multiple-sample methods and 
may lead to a substantial systematic error in GFR of up to 
10-15 mL/min (4,5). 99mTc-DTPA is a chelate of DTPA and 
99mTc. The urinary clearance of 99mTC-DTPA is similar to 
the urinary clearance of 125I-iothalamate. However, plasma 
clearance of 99mTc-DTPA exceeds the urinary clearance 
of the compound by a large and variable amount. Fur-
thermore, the plasma clearance of 99mTc-DTPA exceeds 
the urinary clearance of inulin. These data suggest that 
extrarenal elimination of 99mTc-DTPA occurs, thus limiting 
its use as a marker of glomerular filtration. 51Cr-EDTA is 
a chelate of 51Cr and EDTA. Plasma clearance of 51Cr-
EDTA measured after intravenous bolus injection of the 
compound exceeds its urinary clearance by an average of 
6 mL/min. This may be the result of extrarenal elimination 
of the substance. The error induced by this phenomenon 
is particularly relevant at low levels of GFR. No difference 
was found between the plasma clearance of 51Cr-EDTA 
and of 99mTc-DTPA (4,5). 
On the other hand, Medeiros et al. (7) recently showed 
that plasma clearance of 51Cr-EDTA (51Cr-EDTA-Cl) is a 
precise and accurate measurement of GFR in renal trans-
plant recipients compared with renal inulin clearance (In-Cl). 
Using the Bland and Altman statistical approach to quantify 
the agreement between In-Cl and 51Cr-EDTA-Cl, these in-
vestigators found that two plasma samples for 51Cr-EDTA-Cl 
taken at 4 and 8 h or at 4 and 6 h presented narrow limits of 
agreement (-8.5 to +14.1 and -8.9 to +14.3) and a difference 
(bias) of 2.8 and 2.7 mL/min, respectively (7). 
125I-iothalamate has been used as a glomerular filtration 
marker both in normal subjects and in patients with vari-
ous degrees of renal insufficiency. In a comparative study, 
the plasma clearance of 125I-iothalamate was significantly 
higher than the clearance of 51Cr-EDTA. The difference 
in clearance was reduced by pretreatment of the patients 
with probenecid, suggesting that tubular secretion of 125I-
iothalamate occurs. Additional studies of the urinary clear-
ances measured during constant infusion showed that the 
urinary clearance of unlabeled iothalamate substantially 
exceeded the urinary clearance of inulin in healthy volun-
teers (8). These data suggest that in humans renal tubular 
secretion of iothalamate involves an organic anion transport 
system. This assumption is supported by the finding that 
the urinary clearance of 125I-iothalamate exceeds the inulin 
clearance in subjects with normal kidney function (9). Thus, 
125I-iothalamate appears not to be an ideal marker of glom-
erular filtration. Iothalamate may also be used without the 
radioactive label. Its plasma levels can then be assessed 
by high performance liquid chromatography (10) or X-ray 
fluorescence (11). Taken together, the available radioiso-
topic filtration markers are inferior to inulin for the estimation 
of GFR. However, plasma clearances determined using 
these compounds may be sufficiently accurate for clinical 
practice and for the follow-up of GFR over time.
Creatinine
Serum creatinine (SCr) concentration is the most widely 
used test of renal function outside specialist hospital set-
tings. Nevertheless, several drawbacks have been identi-
fied when SCr is used as a marker of GFR: first, proximal 
tubular cell secretion plays an important role in creatinine 
elimination with declining GFR. Therefore, SCr concen-
trations can be within the normal range even with a GFR 
around 60 mL·min-1·1.73 (m2)-1 suggesting the existence of 
a so-called creatinine blind range (12). Second, the endog-
enous production of creatinine is primarily determined by 
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muscle mass and dietary intake, which probably accounts 
for the variations in SCr levels observed among different 
age, geographic, ethnic, and racial groups (13). Addition-
ally, creatinine production varies considerably intra- and 
inter-individually. This explains the high inter-individual 
variability of SCr, which precludes a reliable estimation 
of kidney function from a single creatinine measurement 
without additional patient data (12). As a result, SCr has 
poor sensitivity for renal failure or mild renal dysfunction, 
particularly in children, malnourished or elderly patients and 
severely ill patients, with consequent under-recognition of 
renal impairment (14,15).
In addition to these problems related to creatinine 
metabolism, creatinine measurement is still technically 
imprecise. Several different methods have been developed, 
with the Jaffé method being the most commonly used. This 
assay is hindered by the interference of non-creatinine 
chromogens (e.g., acetic acid, acetone, pyruvate, glucose, 
ascorbic acid, bilirubin) of up to 20%. With the develop-
ment of enzymatic assays, the problem of interferences 
has been reduced but not eliminated. The development 
of a reference method using isotope dilution mass spec-
trometry has facilitated the measurement of true creatinine 
(16). However, this method is available in only a few highly 
specialized laboratories.
Creatinine clearance (CrCl) is calculated by determin-
ing creatinine concentration in timed urine collections and 
simultaneously in blood using the following equation: CrCl 
(mL/min) = [urinary creatinine (mg/dL) x urine volume (mL/
min)] / [SCr (mg/dL)]. CrCl is considered to be the clinical 
gold standard endogenous method, better than determina-
tion of SCr levels, although it is necessary to remember 
the tubular secretion of creatinine, which may increase 
creatinine excretion more than 2-fold with declining GFR. 
Additionally, the measurement of creatinine clearance 
requires a timed urine collection, which has proven to be 
laborious, inconvenient and prone to collection failure, 
especially in the elderly and children (17).
Equations estimating GFR based on 
creatinine
To circumvent the practical difficulties of CrCl and to 
compensate for interindividual variation in creatinine produc-
tion, several equations have been developed, which include 
anthropometric factors such as gender, age, ethnicity, and 
body size. On the whole, these formulae were calculated 
by regression analysis in large reference populations 
predominantly consisting of patients with chronic kidney 
disease and reduced GFR, who underwent a gold standard 
measurement of GFR. In this setting, the sensitivity to detect 
CKD may be markedly improved. Two formulae are widely 
used in clinical practice for adults: the Cockcroft-Gault (C-G) 
equation (18) and, more recently, the equation developed 
by the MDRD (19). 
The C-G formula was developed in 1973 on the basis 
of data from 249 patients with CrCl from 30 to 130 mL/min. 
It actually estimates CrCl and is not normalized to 1.73 m2 
body surface area. The C-G equation was developed using 
an outdated Jaffé assay for creatinine measurement (18) 
and should be considered with caution when calculated 
using current creatinine measurements, which more closely 
reflect true creatinine. Additionally, the C-G formula also 
leads to an underestimation of GFR in the elderly (20).
The MDRD study equation was presented in 1999 on the 
basis of data from 1628 adult patients with CKD. It estimates 
GFR adjusted for body surface area and was proposed by 
Levey et al. (19) using age, gender, ethnicity, SCr, urea 
nitrogen, and albumin. By avoiding inclusion of weight, 
the formula is less prone to errors from fluid overload and 
obesity. Subsequently, in 2000 a simplified version of the 
original MDRD equation was suggested, which performed 
as well as the original, but required only SCr, age, gender, 
and ethnicity (for African-American individuals) (21). With 
the exception of ethnicity, the other variables required are 
normally provided routinely when a sample is submitted to 
the clinical laboratory. It is therefore much easier for labo-
ratories to report estimated GFR using this formula.
However, certain patient groups were not well rep-
resented in the MDRD study sample. The MDRD study 
predominantly included Caucasian, non-diabetic patients 
with a stable GFR of about 40 mL·min-1·1.73 (m2)-1 (19). 
Therefore, clearance measurements are still required for 
groups who were underrepresented in the original MDRD 
sample in order to fully validate the formula for all patients. 
These include: patients at extremes of age and body size; 
severely malnourished or obese patients; patients with skel-
etal muscle diseases, paraplegia, or quadriplegia, vegetar-
ians, and those with rapidly changing kidney function as in 
acute kidney injury (19,22). The MDRD and C-G equations 
are inappropriate to estimate GFR in healthy individuals 
and have been shown to clearly underestimate GFR above 
approximately 60 mL·min-1·1.73 (m2)-1 and to markedly 
overestimate GFR below approximately 20 mL·min-1·1.73 
(m2)-1 and in nephrotic range proteinuria (23-25). 
Recently, Cirillo et al. (26) demonstrated that the accu-
racy of the MDRD formula tends to decrease in the elderly 
and/or in patients with body mass index <21 and >30 when 
compared to C-G. Both MDRD and C-G equations have 
been reported to be less accurate in populations without 
chronic kidney disease, such as young patients with type 
1 diabetes without microalbuminuria and potential kidney 
donors (27,28). Some studies report the higher accuracy 
of the MDRD equation (26) while others report similar per-
formance of MDRD and C-G equations (29).
In the MDRD study, creatinine was determined and 
calibrated by the kinetic Jaffé method and, similar to the 
C-G equation, a substantial error is introduced when the 
MDRD equation is used with different creatinine assays or 
standards. Calibration of serum creatinine assays to adjust 
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for these differences is not standardized across laboratories, 
leading to substantial variation in values reported among 
laboratories, and, consequently, in error of the estimative 
of GFR by MDRD and C-G equations (30). The simplified 
MDRD equation was recalculated with SCr measurements 
calibrated for an enzymatic assay traceable to an isotope 
dilution mass spectrometry assay (traceable) and was found 
to provide an accurate GFR in patients with CKD, better than 
the C-G equation. However, differences between measured 
and estimated GFR were greater when the estimated GFR 
was 60 mL·min-1·1.73 (m2)-1 or greater (31). 
Recently, Levey et al. (32) developed a new equation, 
the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation, to predict GFR from SCr in adults 
by using a database pooled from 8254 participants in 10 
studies. They showed that the CKD-EPI equation is more 
accurate than the commonly used MDRD equation and 
has lower bias, mainly for estimated GFR greater than 60 
mL·min-1·1.73 (m2)-1, although precision remains subopti-
mal. However, the CKD-EPI equation has some limitations 
such as the fact that few participants had GFR in the normal 
range and were older than 70 years, with incomplete data 
about clinical conditions and medications that might affect 
SCr independent of GFR. In addition, this equation is more 
complex than the MDRD equation and does not overcome 
the limitations of serum creatinine, which is dependent on 
muscle mass, dietary intake, and extrarenal elimination 
(Table 1) (32). 
Nevertheless, the simplified MDRD equation has been 
included as the primary GFR marker in the Practice Guide-
lines for Chronic Kidney Disease, published in 2002 by the 
Kidney Disease Outcomes Quality Initiative of the National 
Kidney Foundation (K/DOQI) and the more recent KDIGO 
guidelines. Moreover, the staging of CKD proposed by the 
K/DOQI and KDIGO is based on GFR estimated by the 
simplified MDRD (Table 2) (2,33).
Cystatin C as a marker of GFR
Since 1985, cystatin C (CysC) has been described as a 
promising endogenous marker of GFR for both adults and 
children. It has a low molecular weight (13 kDa) and is a 
member of the superfamily of cysteine protease inhibitors. 
The gene for CysC is expressed in all nucleated cells, has 
the characteristics of a housekeeping gene and is thought 
to be produced and secreted at a constant rate (34). The 
function of CysC seems to be to protect connective tissue 
from destruction by intracellular enzymes. It may also have 
an antibacterial or antiviral function (35). CysC is a nongly-
cosylated protein that is freely filtered at the glomerulus level 
and almost completely reabsorbed and catabolized, but not 
secreted, by the tubular epithelial cells. Since only small 
amounts are excreted into the urine, its urinary clearance 
cannot be measured. Therefore, the blood concentration 
of CysC depends almost entirely on the GFR and is not 
substantially affected by diet or nutritional status (34). Also, 
CysC is independent of lean muscle mass, age or gender, 
and does not have a circadian rhythm (15,34,36). Because 
of these properties, many investigators have proposed that 
serum concentrations of CysC could serve as an improved 
index of GFR compared with SCr (34).
Nonetheless, some circumstances can interfere with 
serum CysC levels. Large doses of glucocorticoids (500 mg 
methylprednisolone) have been shown to increase serum 
CysC concentration (37). On the other hand, low or medium 
doses of glucocorticoids (20 to 60 mg/day prednisone) do 
not affect serum CysC concentration (38). Additionally, 
thyroid function has an impact on CysC production since, 
as compared with the euthyroid state, CysC levels are 
lower in the hypothyroid and higher in the hyperthyroid 
state (39). Therefore, thyroid function has to be consid-
ered when CysC is used as a marker of renal function. 
Moreover, more recently it was demonstrated that serum 
Table 1. Creatinine-based equations for the estimation of glomerular filtration rate (GFR) in adults.
Cockcroft-Gault equation (18)
GFR = [140 - age (years) x body weight (kg)] / [72 x serum creatinine (mg/dL)] x 0.85 if female 
Simplified MDRD equation (21)
GFR [mL·min-1·1.73 (m2)-1] = 186.3 x [serum creatinine (mg/dL)]-1.154 x [age (years)]-0.203 x (0.742 if female) x (1.210 if African American)
Simplified MDRD equation traceable by isotope dilution mass spectrometry assay (31)
GFR [mL·min-1·1.73 (m2)-1] = 1.75 x [serum creatinine (mg/dL)]-1.154 x [age (years)]-0.203 x (0.742 if female) x (1.212 if African American)
CKD-EPI equation (32)
GFR [mL·min-1·1.73 (m2)-1)] = 141 x min (SCr/k, 1)α x max (SCr/k, 1)-1.209 x 0.993Age x 1.018 (if female) x 1.159 (if black) 
SCr = serum creatinine; k = 0.7 for females and 0.9 for males; α = -0.329 for females and -0.411 for males; min indicates the minimum 
of SCr/k or 1; max indicates the maximum of SCr/k or 1. MDRD = Modification of Diet in Renal Disease Study.
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levels of CysC increase independently of GFR in patients 
with malignancies (40). 
It is interesting to note that, contrary to creatinine 
measurement, which is limited by interferences with other 
chromogens, cystatin C determination does not have any 
interfering factors, except excessively elevated rheumatoid 
factor in vitro (41). Knight et al. (42) found that CysC con-
centrations were significantly associated with increased age, 
male gender, increased weight and height, current smoking, 
and higher C-reactive protein levels, even after adjustment 
for creatinine clearance (42). Nevertheless, it is known that 
the use of CrCl rather than GFR as the gold standard in 
this study (42) limits the credibility of its conclusions. This 
is because the study could not distinguish whether CysC or 
CrCl was the better measure of GFR. Regarding reference 
values, there are no relevant differences between men and 
women. In healthy children, CysC concentration stabilizes 
from the second year of life and the reference range is 
identical to that of adults. Higher CysC concentrations 
reflect maturation of glomerular filtration in neonates and 
are related to decreased kidney function in the elderly (34). 
CysC may identify the gradient of kidney function among 
persons who do not meet conventional definitions of clini-
cal kidney disease. Therefore, the term “preclinical kidney 
disease” was proposed to represent persons with estimated 
GFR >60 mL/min, but who have abnormal concentrations 
of CysC (≥1.0 mg/L) (43).
Several cross-sectional studies have shown that CysC 
has greater sensitivity in detecting mildly reduced GFR in 
CKD than creatinine and other low molecular weight proteins 
(44). Serum CysC concentration increases already with 
mildly reduced GFR of 70 to 90 mL/min, i.e., in the “creati-
nine-blind range” (45). In addition, recent longitudinal studies 
have reported that CysC concentrations increase earlier 
in acute kidney injury in the intensive care unit, in cardiac 
surgery, coronary angiography, after liver transplantation, 
cisplatin chemotherapy, following uninephrectomy, and in 
progressive diabetic nephropathy (46). The performance of 
CysC as an estimator of GFR has been evaluated in large 
diverse populations such as geriatric patients (20), pediatric 
patients with various renal diseases (34), renal transplant 
recipients, type I and type II diabetics, patients with mild 
to moderate CKD of non-diabetic origin (44), patients with 
severe liver or neuromuscular disease, cancer patients, 
and women with preeclampsia (34,46). 
Many investigators have reported the divergence be-
tween elevated CysC concentrations compared to creati-
nine in elderly patients. Hojs et al. (47), studying 144 older 
patients, found a significant correlation between 51Cr-EDTA 
clearance and SCr, serum CysC, the reciprocal of serum 
creatinine (C-G) and the reciprocal of serum CysC, as well 
as CrCl. However, they found that the correlation between 
51Cr-EDTA clearance and serum CysC was significantly 
better than the correlation with SCr (P < 0.05). Likewise, 
the correlation between 51Cr-EDTA clearance and the 
reciprocal of serum CysC was superior to that with the 
reciprocal of serum creatinine (P < 0.003) and calculated 
CrCl (P < 0.003). These results show that serum CysC is 
a more reliable marker of GFR in the elderly than SCr or 
CrCl (47). Several investigators have also concluded that 
CysC performed better than creatinine and even better than 
equations estimating GFR based on creatinine as a GFR 
marker, although others have found no difference (44). 
Schuck et al. (48), in a study of patients with CKD (GFR 
<40 mL·min-1·1.73 (m2)-1), did not observe the superiority of 
CysC over SCr, even though these patients had a significant 
increase in tubular secretion of creatinine from residual 
functioning nephrons. Therefore, to investigate whether 
CysC has any advantage over SCr, Dharnidharka et al. 
(49) performed a meta-analysis that summarized 46 articles 
published up to December 31, 2001, plus eight unpublished 
abstracts containing data on nearly 4500 subjects. Their 
findings confirmed that serum CysC is clearly superior to 
SCr for the detection of impaired GFR in cross-sectional 
studies. Roos et al. (44) performed a systematic review 
(January 1984-February 2006) considering only cross-
sectional, cohort and case-control studies. They compared 
the diagnostic accuracy of CysC with that of SCr in 2007 
Table 2. Classification of stages of chronic kidney disease according to K/DOQI guidelines.
Stage Designation GFR [mL·min-1·1.73 (m2)-1)] Concomitant abnormalities
0 Increased risk for CKD (diabetes, hypertension, etc.) ≥90 (with risk factors for CKD)
1 Renal damage with normal or elevated GFR ≥0 Albuminuria, proteinuria, hematuria
2 Renal damage with mild reduction of GFR 60-90 Albuminuria, proteinuria, hematuria
3 Moderate reduction of GFR 30-59 Proteinuria, hematuria, anemia, 
hypocalcemia, hyperphosphatemia
4 Severe reduction of GFR 15-29 Proteinuria, hematuria, anemia, acidosis, 
hypocalcemia, hyperphosphatemia
5 Renal failure <15 or dialysis Uremia
K/DOQI = Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation (33); GFR = glomerular filtration rate; CKD = 
chronic kidney disease.
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patients from 27 study population groups with renal dys-
function between 60 and 90 mL/min. The results indicated 
that CysC had higher pooled sensitivity (81%) and similar 
specificity (88%) compared to SCr (69 and 88%, respec-
tively). In this meta-analysis, the diagnostic accuracy of 
impaired renal function favored CysC (44).
Interestingly, although CysC measurement is probably 
accepted to be superior to creatinine to measure GFR, an 
important limitation of the use of CysC in routine assessment 
of kidney function is that CysC reference ranges vary widely 
when different cystatin assays are used. There are two major 
methods to measure CysC: particle-enhanced immunotur-
bidimetric immunoassay (PETIA) and immunonephelomet-
ric immunoassay (PENIA). Another method, ELISA kit, has 
a poor performance in terms of the analytical coefficient of 
variation compared to PETIA and PENIA (50).
Equations estimating GFR based on 
cystatin C 
Several groups have recently developed equations to 
calculate GFR from serum CysC using approaches similar 
to those described for creatinine. In contrast to the MDRD 
equation, which was calculated from a large population in a 
multicenter study, CysC-based equations were created and 
validated in smaller samples using different gold standard 
measurements for GFR. Table 3 highlights some CysC-
based equations for adults (29,45,51-56). 
Many investigators have compared CysC-based 
equations to the C-G and the simplified MDRD equations. 
The vast majority, when comparing bias, precision, ac-
curacy, and correlation, found CysC-based equations to 
be superior to creatinine-based equations as estimates 
of GFR (45,52,53), while some reported no difference in 
the performance of CysC- and creatinine-based equations 
(29,54). Recently, in order to improve the estimated kid-
ney function, estimated GFR equations were developed, 
which incorporate both SCr and CysC. These equations, 
including serum CysC in combination with SCr, age, gender 
and race, performed better compared to the creatinine- 
and CysC-based equations regarding to bias, precision 
and accuracy (57-59). In this setting, Stevens et al. (56) 
developed new equations to estimate GFR using serum 
CysC alone or serum CysC and SCr in combination with 
demographic variables. The individuals were screened for 
3 CKD studies in the United States (N = 2980) and a clinical 
population was studied in Paris, France (N = 438). GFR 
was measured using urinary clearance of 125I-iothalamate 
in the US studies and 51Cr-EDTA in the Paris study. The 
equations were developed by using linear regression with 
log GFR, and the best-fitting equation included both crea-
tinine and cystatin as well as age, gender and race (Table 
3) (56). The studies also showed that serum CysC alone 
estimates GFR as accurately as SCr levels adjusted for 
age, gender and race. However, in another study, Urbaniak 
et al. (60) did not find any improvement in predicting GFR 
using this combination. 
Conclusion
We conclude that serum CysC has greater sensitivity 
in detecting reduced GFR in CKD than serum creatinine. 
However, further studies are necessary to compare CysC 
concentrations and CysC-based equations with MDRD 
equation and to clarify which one can better detect small 
reductions in kidney function within the normal range. This 
is because their diagnostic accuracies are very similar. 
The determination of plasma CysC levels is more expen-
sive than routine plasma creatinine determination and 
the absence of very significant advantages could explain 
Table 3. Cystatin C-based equations for the estimation of glomerular filtration rate in adults.
GFR gold standard Population References
Immuno-nephelometric assay
GFR = 80.35 / CysC (mg/L) - 4.32 125I-iothalamate CKD (N = 123) 45
GFR = 77.239 x CysC (mg/L)-1.2623 Iohexol (N = 100) 55
GFR = 86.7 / CysC (mg/L) - 4.2 99mTc-DTPA Diabetics (N = 251) 54
GFR = 66.8 x CysC (mg/L)-1.30 Iothalamate CKD (N = 357) 29
GFR = 177.6 x SCr-0.65 x CysC-0.57 x age-0.20 x 
0.82 (if female) x 1.11 (if black)
125I-iothalamate 51Cr-EDTA CKD (N = 3418) 56
Immuno-turbidimetric assay
GFR = 87.1 / CysC (mg/L) - 6.87 Iohexol (N = 40; 29 diabetics) 51
GFR = 99.434 x CysC (mg/L)-1.5837 Iohexol (N = 100) 55
GFR = 99.19 x CysC (mg/L)-1.713  x 0.823 (if female) Iohexol (N = 451) 52
GFR = 87.62 x CysC (mg/L)-1.693 x 0.94 (if female) Iohexol (N = 451) 53
GFR = glomerular filtration rate; CKD = chronic kidney disease; CysC = Cystatin C; SCr = serum creatinine.
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its limited use in daily clinical practice. Therefore, before 
these CysC-based equations are included in routine clinical 
practice, they require standardization of the CysC assay, 
availability of cost-effective assays, further investigation 
in multiple clinical situations and prospective studies to 
determine whether the combination of creatinine and CysC 
in one prediction formula may yield superior results. 
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